Integrated Filing — IndAS



General information about company

Scrip Code 539524
NSE Symbol LALPATHLAB
MSEI Symbol NOTLISTED
ISIN INE600L01024
Name of company Dr. Lal Path Labs Ltd.
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 30-04-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 27-03-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.
Start date and time of board meeting 30-04-2026   11:30:00
End date and time of board meeting 30-04-2026   15:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 70,270.00 2,76,290.00
Other income 2,400.00 10,130.00
Total income 72,670.00 2,86,420.00
2 Expenses
(a) Cost of materials consumed 13,520.00 53,460.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 12,880.00 50,330.00
(e) Finance costs 610.00 2,280.00
(f) Depreciation, depletion and amortisation expense 4,460.00 16,180.00
(f) Other Expenses
1 Fees to collection centers/channel partners 10,060.00 40,240.00
2 Other expenses 15,130.00 54,010.00
Total other expenses 25,190.00 94,250.00
Total expenses 56,660.00 2,16,500.00
3 Total profit before exceptional items and tax 16,010.00 69,920.00
4 Exceptional items 0.00 (3,010.00)
5 Total profit before tax 16,010.00 66,910.00
6 Tax expense
7 Current tax 2,740.00 15,920.00
8 Deferred tax 50.00 10.00
9 Total tax expenses 2,790.00 15,930.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 13,220.00 50,980.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 13,220.00 50,980.00
17 Other comprehensive income net of taxes 430.00 520.00
18 Total Comprehensive Income for the period 13,650.00 51,500.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 13,130.00 50,480.00
Total profit or loss, attributable to non-controlling interests 90.00 500.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 13,560.00 51,000.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 90.00 500.00
21 Details of equity share capital
Paid-up equity share capital 16,760.00 16,760.00
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 2,34,060.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 7.86 30.24
Diluted earnings (loss) per share from continuing operations 7.85 30.2
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 7.86 30.24
Diluted earnings (loss) per share from continuing and discontinued operations 7.85 30.2
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 April, 2026 respectively. The consolidated financial results for the year ended 31 March, 2026 have been audited and for the quarter ended 31 March, 2026 have been reviewed by the statutory auditors of the Company and they have issued an unmodified report thereon. ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as the Group'). iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India. iv. Figures for the quarter ended 31 March, 2026 and 31 March, 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the quarter ended 31 December, 2025 and 31 December, 2024 respectively, which were subjected to limited review. v. During the year ended 31 March 2026, Dr. Lal Pathlabs Limited (Parent Company) has issued 4,000 equity shares of face value of INR 10 each respectively, on exercise of employee stock options. Further, during the year ended 31 March 2026, the Parent Company has issued 183,775 equity shares of face value of INR 10 each , to Dr. Lal Pathlabs Employee Welfare Trust under Employee Stock Option Plan, 2022 (ESOP Plan, 2022). vi. The Board of Directors of the Parent Company at their meeting held on 30 April 2026 has proposed final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) of INR 4 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2026. The total dividend for the year including the final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) is INR 20.5 per equity share having face value of INR 10 each. The Board of Directors of the Parent Company have approved third interim dividend of INR 3.5 per equity share (face value of INR 10 each) at their meeting held on 30 January, 2026 and this was paid on 16 February,2026. The Board of Directors of the Parent Company had approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025 which was paid on 17 November,2025. The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 which was paid on 14 August, 2025 The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025. vii. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, has been dissolved and its name has been struck off, with effect from the date of publication of gazette notification dated September 13, 2024. viii. The Hon’ble Allahabad Bench of the National Company Law Tribunal (‘Hon’ble Tribunal’ or ‘NCLT’) sanctioned the Scheme of Amalgamation ('Scheme') between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024. The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company.Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the ‘pooling of interests’ method in accordance with Ind AS 103 “Business Combinations” and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company. ix. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited (SDIPL), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis. The Hon’ble National Company Law Tribunal (“NCLT”), Mumbai Bench vide its order dated February 27, 2026, approved dissolution of SDIPL. The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year ended 31 March 2025. x. The shareholders of the Parent Company on December 07, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of Rs.10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed December 19, 2025 as record rate. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on December 22, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the year ended March 31, 2025 have been restated to give effect to the allotment of the bonus shares. xi. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (‘Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Group has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by 301 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount as “Impact of Labour Codes” under “Exceptional Item” in the Consolidated Statement of Profit and Loss for the three months ended December 31, 2025. The Group continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits. xii. As at 31st March,2026, the Parent company has the following subsidiaries: Subsidiaries Paliwal Diagnostics Private Limited Dr. Lal PathLabs Nepal Private Limited Dr. Lal PathLabs Bangladesh Private Limited Dr. Lal Ventures Private Limited PathLabs Unifiers Private Limited Step-down subsidiaries Centrapath Labs Private Limited APRL PathLabs Private Limited Chanre Laboratory Private Limited JV/Associate Company- Nil xiii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. xiv. During the year, the company has regrouped manpower cost aggregating to INR 266 million for the year ended 31 March, 2025, INR 80 million for quarter ended 31 December 2025, INR 70 million for the quarter ended 31 March 2025, representing collection and transportation charges carried out through third party from employee benefit expenses to other expenses in line with the nature of contract xv. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities and Annexure - B for Consolidated Cash Flow Statement



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 48,380.00
Capital work-in-progress 550.00
Investment property 3,280.00
Goodwill 54,820.00
Other intangible assets 19,150.00
Intangible assets under development 100.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current 0.00
Loans, non-current 10.00
Other non-current financial assets
1 Other financial assets 20,930.00
Total of other non-current financial assets 20,930.00
Total non-current financial assets 20,940.00
Deferred tax assets (net) 8,750.00
Other non-current assets
1 Non-current tax assets (net) 1,910.00
2 Other non-current assets 60.00
Total of other non-current assets 1,970.00
Total non-current assets 1,57,940.00
2 Current assets
Inventories 4,390.00
Current financial asset
Current investments 42,260.00
Trade receivables, current 11,070.00
Cash and cash equivalents 24,280.00
Bank balance other than cash and cash equivalents 66,670.00
Loans, current 180.00
Other current financial assets
Total of other current financial assets 5,580.00
Total current financial assets 1,50,040.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 2,230.00
Total of other current assets 2,230.00
Total current assets 1,56,660.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 3,14,600.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 16,760.00
Other equity 2,34,060.00
Total equity attributable to owners of parent 2,50,820.00
Non controlling interest 3,310.00
Total equity 2,54,130.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 14,540.00
Total of other non-current financial liabilities 14,540.00
Total non-current financial liabilities 14,540.00
Provisions, non-current 260.00
Deferred tax liabilities (net) 600.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 15,400.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,710.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 16,350.00
Total Trade payable 18,060.00
Other current financial liabilities
1 Other financial liabilities 9,360.00
2 Lease liabilities 5,360.00
Total of other current financial liabilities 14,720.00
Total current financial liabilities 32,780.00
Other current liabilities 4,200.00
1 Other current liabilities 4,200.00
Total of other current liabilities 4,200.00
Provisions, current 7,380.00
Current tax liabilities (Net) 710.00
Deferred government grants, Current 0.00
Total current liabilities 45,070.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 60,470.00
Total equity and liabilites 3,14,600.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of the defined benefit obligations 570.00 670.00
Total Amount of items that will not be reclassified to profit and loss 570.00 670.00
2 Income tax relating to items that will not be reclassified to profit or loss 140.00 170.00
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences on translation of foreign operations 0.00 20.00
Total Amount of items that will be reclassified to profit and loss 0.00 20.00
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 430.00 520.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 66,910.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2,280.00
Adjustments for decrease (increase) in inventories (770.00)
Adjustments for decrease (increase) in trade receivables, current (2,680.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 60.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (270.00)
Adjustments for other financial assets, current (80.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,350.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (100.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 16,180.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 4,600.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 550.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 20.00
Adjustments for dividend income 0.00
Adjustments for interest income 6,700.00
Adjustments for share-based payments 2,380.00
Adjustments for fair value losses (gains) (1,940.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (1,170.00)
Other adjustments to reconcile profit (loss) 490.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 14,200.00
Net cash flows from (used in) operations 81,110.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 17,540.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 63,570.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 50.00
Purchase of property, plant and equipment 16,700.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 640.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 6,640.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (31,540.00)
Net cash flows from (used in) investing activities (42,190.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 1,860.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 3,680.00
Dividends paid 22,260.00
Interest paid 2,280.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (26,360.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (4,980.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (4,980.00)
Cash and cash equivalents cash flow statement at beginning of period 29,260.00
Cash and cash equivalents cash flow statement at end of period 24,280.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells LLP Yes 31-07-2027